[Leadless cardiac pacemaker : Overview, tips, and tricks]

Leadless pacemakers (LP) have emerged as a validated alternative to conventional transvenous systems, offering significant complication reduction by eliminating leads and device pockets. Current LP technologies include the Micra™ series (Medtronic, Minneapolis, MN, USA) and the modular Aveir™ system (Abbott Laboratories, Abbott Park, IL, USA), enabling the first fully leadless dual-chamber pacing. Clinical benefits are most evident in patients at high infection risk or with venous access limitations. Advances such as atrioventricular (AV)-synchronous pacing and long battery life have broadened indications, while maintaining stable device performance. Key challenges remain in end-of-life management and guideline integration. Future directions may involve combinations with subcutaneous implantable cardioverter-defibrillators (ICDs) or energy-harvesting technologies, further expanding therapeutic applications.